A Better Newspaper

Developing Story

Patent Enablement Doctrine – Supreme Court Petition & Federal Circuit Rulings

A pending Supreme Court certiorari petition challenges a Federal Circuit ruling that created an 'after-arising technology' exception to the patent enablement requirement under 35 U.S.C. §112. A related October 2025 Federal Circuit decision affirming invalidation of a Brita patent for lack of enablement underscores the doctrine's growing litigation significance.

Importance: 55%Confidence: 75%Mentions: 1Updated: August 4, 2026
## Overview A developing legal debate centers on the enablement requirement of 35 U.S.C. §112, which requires that a patent claim as construed must be enabled as to its full scope. A petition for certiorari is currently pending before the United States Supreme Court raising "serious concerns as to fundamental principles of patent law, especially relating to the enablement requirement" (IPWatchdog, October 5). ## The Federal Circuit Ruling at Issue The petition arises from a U.S. Court of Appeals for the Federal Circuit (CAFC) decision that carved out an "after-arising technology" exception from the general enablement requirement. Critics argue the ruling "did violence to other important rules" and could have "far-reaching consequences" for patent holders (IPWatchdog, October 5). ## Related Federal Circuit Activity In a related but separate case, the CAFC issued a precedential decision on October 15 in *Brita LP v. International Trade Commission*, affirming the ITC's finding that claims of a Brita patent for a water filtration "gravity flow" system are invalid for lacking adequate written description and enablement. The opinion was authored by Circuit Judge Prost and joined by Judges Reyna and Chen (IPWatchdog, October 16). This ruling illustrates the practical stakes of enablement doctrine currently being litigated at the Federal Circuit and potentially the Supreme Court. ## Why It Matters Enablement is a foundational patent validity doctrine. If the Supreme Court grants certiorari and revisits the standard, the ruling could reshape how courts assess claim scope versus disclosed embodiments—an issue with significant implications for pharmaceutical, biotech, and technology patent portfolios where claims often extend beyond initially disclosed embodiments to cover later-developed variations. ## Entities to Track - United States Supreme Court (pending cert petition) - U.S. Court of Appeals for the Federal Circuit - International Trade Commission - Brita LP